Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the oncology based in-vivo cro market grown in recent years?

The in-vivo CRO market, primarily focused on oncology, has seen robust growth of late. Expanding from a size of $1.39 billion in 2024 to a projected $1.5 billion in 2025, it promises a compound annual growth rate (CAGR) of 8.0%. This upward trend in the historical period can be traced back to factors such as a heightened emphasis on oncology treatments, a rising number of cancer cases, a shift towards individualized healthcare, the prospering pharmaceutical industry, and the rising demand for therapies targeted at specific ailments.

How is the oncology based in-vivo cro market size expected to evolve during the forecast period?

The size of the in-vivo CRO market, primarily focused on oncology, is projected to undergo substantial expansion in the coming few years, reaching “$2.28 billion by 2029” with a Compound Annual Growth Rate (CAGR) of 10.9%. Factors contributing to this expansion during the forecasted period include burgeoning market prospects, the transition towards immuno-oncology treatments, an increase in oncology-related clinical trials, precision and targeted therapies. Regenerative and cell therapies, the need for expedited drug development, the integration of digitalization and data analytics, attention to the tumor microenvironment and the growth in biologics and immunotherapies are predicted to dominate trends during the forecast period.

Get your oncology based in-vivo cro market report here!

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Which key drivers are propelling the oncology based in-vivo cro market’s growth?

The surge in cancer instances is anticipated to boost the growth of the oncology-based in-vivo CRO market. Cancer is a collection of diseases characterized by unrestricted cell division that can arise from any organ or tissue and spread throughout the body via the blood and lymph systems. The development of novel drugs and devices for diagnosing and treating cancer undergoes numerous preclinical trials, clinical trials, and regulatory processes before they are commercially available. An oncology-based in-vivo CRO is a research services firm employed by a sponsor company to perform all or portions of a preclinical in-vivo study before testing a drug or device on humans. The surge in cancer prevalence has amplified the desire for innovative medical treatments, enhancing the oncology-based in-vivo CRO market’s growth. As an example, in April 2024, the American Cancer Society, an American nonprofit organization, reported approximately 609,000 cancer fatalities and 1.9 million new cancer diagnoses in 2022. Around 620,000 cancer deaths are projected in 2024, indicating a minor rise in mortality rates. This rise in cancer occurrences is the driving force behind the expansion of the oncology-based in-vitro CRO market.

What are the market segments in the oncology based in-vivo cro industry?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Hospitals, Rehabilitation Centers

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which leading companies are shaping the growth of the oncology based in-vivo cro market?

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

What key trends are currently impacting the oncology based in-vivo cro market’s development?

In a bid to gain an edge over competitors in the oncology-centric in vivo CRO market, leading companies are turning to personalized oncology models. By using patient-derived xenografts (PDXs), these models allow for the creation of bespoke treatment plans, which amplifies the pertinence and effectiveness of preclinical studies. An example of this is Charles River Laboratories, a life sciences company based in the U.S. that in 2022 unveiled its OncoMouse platform. PDX technology is utilized within the platform for improved precision in tumour modelling. The platform also offers large scale screening capabilities and continuous monitoring of tumour growth, which permits swift evaluations of therapeutic reactions. Furthermore, it employs integrated data analytics for the calibration of treatment protocols that accord with individual patient characteristics. These developments indicate a progression towards more effective, patient-focused method in cancer research.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521

Which geographic areas are influencing the growth of the oncology based in-vivo cro market?

North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Oncology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

Community Oncology Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: